No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

To the editor: Romiplostim and eltrombopag (a synthetic fusion peptibody and a nonpeptide molecule, respectively) are second-generation thrombopoietin mimetics/agonists that are structurally dissimilar to thrombopoietin and do not induce the formation of autoantibodies.[1][1][⇓][2]–[3][3] They